Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
Scripps News on MSN8d
FDA approves standalone nasal spray to treat depressionA one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions ... in their symptoms as early as 24 hours without the need for daily oral ...
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as ... symptoms as early as 24 hours and at 28 days – without ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback